Appendix 1: Vaccine information
Preparations for the nationwide roll-out of the Covid-19 vaccine.
| Name | Technology | Number of doses purchased | Number of doses needed for each person | Medsafe status |
|---|---|---|---|---|
| Pfizer-BioNTech | RNA | 10 million | Two | Approved under section 23 of the Medicines Act, with conditions. This is called a provisional approval. |
| Janssen Pharmaceutica | Non-replicating viral vector | 5 million | One | Application received, some data under evaluation, further data to be provided by sponsor. |
| Novavax | Protein subunit | 10.72 million | Two | Has not yet made an application for approval. |
| AstraZeneca/Oxford | Non-replicating viral vector | 7.6 million | Two | Application received, some data under evaluation, further data to be provided by sponsor. |